# Phase 1 Study With OAB Assessing the Safety and Activity of hMaxi-K Gene Transfer

> **NCT01870037** · PHASE1 · COMPLETED · sponsor: **Urovant Sciences GmbH** · enrollment: 13 (actual)

## Conditions studied

- Overactive Bladder

## Interventions

- **DRUG:** Placebo (PBS-20% sucrose)
- **DRUG:** hMaxi-K

## Key facts

- **NCT ID:** NCT01870037
- **Lead sponsor:** Urovant Sciences GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-01
- **Primary completion:** 2017-06
- **Final completion:** 2018-02-17
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2019-05-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01870037

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01870037, "Phase 1 Study With OAB Assessing the Safety and Activity of hMaxi-K Gene Transfer". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT01870037. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*